IDIX Major Shareholders
[Updated for small “true-up” purchase by NVS on 6/8/10.]
The percentages in the table are based on 78.9.M diluted shares,
the count I use for valuation purposes (#msg-49785732); these
percentages differ from the ones reported in SEC filings.
Shares Stake
Novartis 31,324,187 39.7%
T Rowe Price 8,101,442† 10.3%
JP Sommadossi (CEO) 4,226,000* 5.4%
BB/MPM Capital 3,321,534 4.2%
GlaxoSmithKline 2,474,527 3.1%
†Based on Form 13G filed 5/10/10.
*Includes all 2.2M options, whether or not vested.